MSD’s Q1 2026 results reflect continued strength in oncology and animal health, plus increasing contributions from launches. Our company announced Q1 worldwide sales of $16.3 billion.
“We are moving with speed to transform our portfolio to one with a diversified set of growth drivers across a broad set of therapeutic areas,” said Rob Davis, chairman and CEO. “During the first quarter, we continued to strengthen our pipeline with science-led business development, including our planned acquisition of Terns. We also achieved several important milestones, such as our most recent approval in HIV, marking a new chapter in our research and longstanding commitment to people living with HIV. I am pleased with our progress and excited for what’s ahead, as we enter a particularly robust period of Phase 3 data readouts and deliver on the promise of our pipeline for patients.”
MSD anticipates full-year 2026 worldwide sales to be between $65.8 billion and $67.0 billion.
Take a look at the infographic below for more details on Q1 2026 results.
